RESULT OF OFFERING IN SCN

(NGM:SCN)

On November 15, 2007, the Board of SCN resolved to set a share issue of 2,050,000 new shares at NOK 12.90 per share in connection with the listing of the Company’s shares on Oslo Axess. Through the issue, SCN complies with Oslo Børs’ requirements: a minimum 100 Norwegian shareholders, a minimum of 25% of total shares being held by the general public and the completion of a SEK 30 million share issue.

Reference is made to the Prospectus dated 5 November 2007 regarding the public offering of shares in connection with the listing of Scandinavian Clinical Nutrition i Sverige AB (publ) on Oslo Axess.

The subscription period for the offering was closed on 15 November 2007 and was successfully completed. After the offering, SCN will have a total of 14,790,724 shares and more than 300 shareholders.

The shares of SCN are expected to be listed on Oslo Axess on or about 22 November 2007, and will trade under the ticker code “SCN”.

Terra Securities ASA has acted as Lead Manager for the offering in connection with the listing of SCN’s shares on Oslo Axess.

For more information, please contact:

Ulf Söderberg, CEO, ulf.soderberg@scnutrition.com, +46 708 13 22 81

Anders Struksnes, Senior Vice President, anders.struksnes@scnutrition.com, +47 911 98 942

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Membraseven, Coldizin, Immulina and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth both in Sweden and in the company’s export markets. The SCN share is listed for trade on NGM Equity.